Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Catholic Genetic Laboratory Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Int J Mol Sci. 2023 Feb 6;24(4):3177. doi: 10.3390/ijms24043177.
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries. However, CLL is relatively rare in Asia; its genetic features are rarely studied. Here, we aimed to genetically characterize Korean CLL patients and to elucidate the genetic and clinical associations based on data obtained from 113 patients at a single Korean institute. We used next-generation sequencing to explore the multi-gene mutational data and immunoglobulin heavy chain variable gene clonality with somatic hypermutation (SHM). (28.3%), including L265P (11.5%) and V217F (13.3%), was the most frequently mutated gene, followed by (6.2%), (5.3%), (5.3%), and (4.4%). -mutated CLL was characterized by SHM and atypical immunophenotype with fewer cytogenetic abnormalities. The 5-year time to treatment (TTT) of the overall cohort was 49.8% ± 8.2% (mean ± standard deviation) and the 5-year overall survival was 86.2% ± 5.8%. Patients with SHM, isolated del(13q), -wild type, and -wild type showed better results than those without these conditions. In the subgroup analyses, patients with SHM and L265P presented shorter TTT than patients with SHM but not L265P. In contrast, V217F was associated with a higher SHM percentage and showed a favorable prognosis. Our study revealed the distinct characteristics of Korean CLL patients with high frequencies of mutations and their clinical relevance.
慢性淋巴细胞白血病(CLL)是西方国家最常见的成人白血病。然而,CLL 在亚洲相对较少见;其遗传特征很少被研究。在这里,我们旨在对韩国 CLL 患者进行基因特征分析,并根据单一韩国机构的 113 名患者的数据阐明遗传和临床相关性。我们使用下一代测序技术探索多基因突变数据和体细胞高频突变(SHM)的免疫球蛋白重链可变基因克隆性。 在我们的研究中,最常见的突变基因为 (28.3%),包括 L265P(11.5%)和 V217F(13.3%),其次是 (6.2%)、 (5.3%)、 (5.3%)和 (4.4%)。 在所有突变基因中, (34.3%)突变与更好的预后相关,包括较短的无进展生存期(PFS)和总生存期(OS),其次是 (19.3%)和 (16.4%)。 突变的 CLL 具有 SHM 和非典型免疫表型,细胞遗传学异常较少。整个队列的 5 年治疗时间(TTT)为 49.8%±8.2%(均值±标准差),5 年总生存率为 86.2%±5.8%。具有 SHM、孤立的 del(13q)、-野生型和 -野生型的患者比不具有这些条件的患者结果更好。在亚组分析中,具有 SHM 和 L265P 的患者 TTT 短于具有 SHM 但没有 L265P 的患者。相比之下,V217F 与更高的 SHM 百分比相关,表现出良好的预后。我们的研究揭示了韩国 CLL 患者的独特特征,包括高频 突变及其临床相关性。